Q-omics provides the consensus-scored SNRNP35 profile across patient tissues and cancer cell-line models. SNRNP35 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNRNP35 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, SNRNP35 RNA expression shows 17,584 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where SNRNP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRNP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRNP35 survival associations across molecular data types. SNRNP35 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRNP35 RNA expression–survival associations across cancer types. High SNRNP35 expression shows unfavorable associations in KIRC, UVM, ACC and LIHC, but favorable associations in UCEC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNRNP35 RNA expression.
This table summarizes SNRNP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SNRNP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRNP35 shows lower tumor expression in LUAD and KICH and higher tumor expression in LIHC, KIRC, ESCA and STAD. The LIHC box plot shows higher SNRNP35 RNA expression in tumor versus normal tissue (log2 FC = +0.943, t-test p < 0.001).
This table shows molecular features associated with SNRNP35 in patient tissues and cancer cell lines. In patient samples, SNRNP35 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRNP35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
